Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Comparison of cell-surface TFPIalpha and beta.

O Piro1, G J Broze

  • 1Division of Hematology, Washington University School of Medicine, St Louis, MO, USA.

Journal of Thrombosis and Haemostasis : JTH
|October 26, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Suppressing protein Z-dependent inhibition of factor Xa improves coagulation in hemophilia A.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Re-evaluation of mouse tissue factor pathway inhibitor and comparison of mouse and human tissue factor pathway inhibitor physiology.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Evidence of clinically significant extravascular stores of factor IX.

Journal of thrombosis and haemostasis : JTH·2013
Same author

Protein Z, protein Z-dependent protease inhibitor (serpinA10), and the acute-phase response.

Journal of thrombosis and haemostasis : JTH·2012
Same author

The C-terminus of tissue factor pathway inhibitor α is required for its interaction with factors V and Va.

Journal of thrombosis and haemostasis : JTH·2012
Same author

Tissue factor pathway inhibitor endocytosis.

Trends in cardiovascular medicine·2011

Tissue factor pathway inhibitor (TFPI) has two forms, TFPIalpha and TFPIbeta, differing in glycosylation and cell surface activity. TFPIbeta contributes more to inhibiting Factor Xa activation, suggesting distinct roles for these TFPI variants.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Background:

  • Tissue factor pathway inhibitor (TFPI) is primarily synthesized by endothelial cells.
  • Alternative mRNA splicing produces two TFPI isoforms: TFPIalpha and TFPIbeta.
  • Both isoforms can anchor to the cell surface via glycosylphosphatidyl-inositol (GPI)-mediated mechanisms.

Purpose of the Study:

  • To compare the structural characteristics and functional properties of TFPIalpha and TFPIbeta.
  • To investigate the glycosylation patterns and cellular activities of the two TFPI forms.

Main Methods:

  • Differential glycosidase treatments were used to analyze TFPI isoform glycosylation.
  • mRNA and protein synthesis of TFPI isoforms were assessed in ECV304 cells stimulated with inflammatory cytokines.

Related Experiment Videos

  • Small interfering RNA (siRNA) was employed to generate cell lines with reduced TFPIalpha or TFPIbeta expression.
  • Cell-surface TFPI activity was quantified using a chromogenic assay measuring FXa activation inhibition.

    • Main Results:

    • Deglycosylation studies revealed TFPIbeta has greater sialylation of O-linked carbohydrates compared to TFPIalpha, explaining their differing molecular masses.
    • Inflammatory stimuli (IL-1beta, LPS, TNFalpha) did not alter mRNA or protein levels of either TFPI form.
    • TFPIalpha constituted 80% of surface-bound TFPI, but TFPIbeta accounted for the majority of cellular inhibitory activity against FVIIa/TF.

    Conclusions:

    • TFPIalpha and TFPIbeta exhibit distinct glycosylation profiles and functional contributions to cell surface TFPI activity.
    • TFPIbeta plays a more significant role in inhibiting the FVIIa/TF complex, suggesting specialized functions.
    • The findings indicate potential distinct roles for TFPIalpha and TFPIbeta beyond their shared function in the coagulation cascade.